Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer

doi:10.3969/j.issn.1006-7795.2016.06.011

Abstract

Abstract: According to clinical guidelines, cisplatin-based chemotherapy given in adjuvant setting of non-small cell lung cancer (NSCLC) can contribute to the prolongation of survival. However, chemotherapy has reached a therapeutic plateau. It has been confirmed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) provided a dramatic response to patients with advanced EGFR-mutant NSCLC. The role of EGFR TKI in adjuvant setting of NSCLC still remains unclear. The purpose of this review is to evaluate the current and available data.

Key words: lung cancer, early stage, EGFR mutation, adjuvant therapy, targeted therapy

CLC Number:

R734.2

Yao Shuyang, Zhi Xiuyi. Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer[J]. Journal of Capital Medical University, 2016, 37(6): 773-776.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2016.06.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2016/V37/I6/773

References

[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] Arriagada R, Dunant A, Pignon J P, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer[J].J Clin Oncol,2010, 28(1): 35-42.
[3] Butts C A, Ding K, Seymour L, et al. Randomized phase Ⅲ trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and Ⅱ non-small-cell lung cancer: updated survival analysis of JBR-10[J]. J Clin Oncol,2010, 28(1): 29-34.
[4] Pignon J P, Tribodet H, Scagliotti G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J].J Clin Oncol,2008, 26(21): 3552-3559.
[5] Wu Y L, Zhou C, Hu C P,et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J].Lancet Oncol,2014, 15(2): 213-222.
[6] Han J Y, Park K, Kim S W,et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol,2012, 30(10): 1122-1128.
[7] Mok T S, Wu Y L, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med,2009, 361(10): 947-957.
[8] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010, 362(25): 2380-2388.
[9] Zhou C, Wu Y L, Chen G,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol,2011, 12(8): 735-742.
[10] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J].Lancet Oncol,2012, 13(3): 239-246.
[11] Yu Z H, Lin S H, Balter P, et al. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers[J].Radiother Oncol, 2012, 104(1): 33-38.
[12] Cedres S, Nunez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-179.
[13] Dematteo R P, Ballman K V, Antonescu C R, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2009, 373(9669): 1097-1104.
[14] Goss G D, O'Callaghan C, Lorimer I,et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J].J Clin Oncol, 2013, 31(27):3320-3326.
[15] Thatcher N, Chang A, Parikh P,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)[J]. Lancet, 2005, 366(9496): 1527-1537.
[16] Zhai H, Zhong W, Yang X, et al. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer[J].Transl Lung Cancer Res, 2015, 4(1): 82-93.
[17] Janjigian Y Y, Park B J, Zakowski M F, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]. J Thorac Oncol, 2011, 6(3): 569-575.
[18] Pennell N A, Neal J W, Govindan R, et al. SELECT: a multicenter phase Ⅱ trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC[J]. J Clin Oncol, 2014, 32(5S): Abstr7514.
[19] Kelly K, Altorki N K, Eberhardt W E, et al. Adjuvant Erlotinib Versus Placebo in Patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A randomized, double-blind, phase III trial[J]. J Clin Oncol, 33(34):4007-4014.
[20] Feng S, Wang Y, Cai K,et al. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy[J]. PLoS One, 2015, 10(10): e0140794.
[21] Li N, Ou W, Ye X,et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage ⅢA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase Ⅱ study[J].Ann Surg Oncol, 2014, 21(6): 2091-2096.
[22] Lv C, An C, Feng Q, et al. A Retrospective Study of Stage I to Ⅲa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?[J]. Clin Lung Cancer, 2015, 16(6): e173-181.
[23] Tada H, Takeda K, Nakagawa K,et al. Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L)[J].Annals of Oncology, 2012,10:23.